Has highly active antiretroviral therapy increased the time to seroreversion in HIV exposed but uninfected children?

Background: Since the introduction of highly active antiretroviral therapy (HAART) for prevention of mother-to-child transmission of human immunodeficiency virus (HIV) in pregnancy in the United States, the time of seroreversion in infants born to HIV-infected mothers has not been documented. The objective of this study was to determine the timing of clearance of HIV antibodies and to identify any associated biological and clinical factors.

Methods: A retrospective analysis of infants who remained uninfected after perinatal HIV exposure was performed.